Journal of Medicinal Chemistry · 2009 · 69 citations · 24 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryEnzymologyStructure-activity RelationshipsDiabetes Mellitus BiochemistryDiabetes PharmacotherapyEnzyme InhibitionEnzyme TargetsFructose MetabolismPotency OptimizationAnimal Disease ModelsAntidiabetic Drug TherapyBenzimidazole ChemistryBenzimidazole SynthesisGlucose-lowering TherapyInhibitor ScreeningLead Compound OptimizationPurine Analogues
Efforts to enhance the inhibitory potency of the initial purine series of fructose-1,6-bisphosphatase (FBPase) inhibitors led to the discovery of a series of benzimidazole analogues with human FBPase IC(50)s < 100 nM. Inhibitor 4.4 emerged as a lead compound based on its potent inhibition of human liver FBPase (IC(50) = 55 nM) and significant glucose lowering in normal fasted rats. Intravenous administration of 4.4 to Zucker diabetic fatty rats led to rapid and robust glucose lowering, thereby providing the first evidence that FBPase inhibitors could improve glycemia in animal models of type 2 diabetes.
24
Prodrugs of Phosphates and Phosphonates
Scott J. Hecker, Mark D. Erion · Journal of Medicinal Chemistry · 2008 · 412 citations
Isabelle Lefèbvre, Christian Périgaud, Alain Pompon et al. · Journal of Medicinal Chemistry · 1995 · 232 citations
Mark D. Erion, Paul D. van Poelje, Qun Dang et al. · Proceedings of the National Academy of Sciences · 2005 · 162 citations